Logo
x

Search

Subscribe Now

Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic P...

  • November 21, 2024
Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

  • November 7, 2024
Surrozen Collaborates with TCGFB for Developing TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Collaborates with TCGFB for Developing TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

  • November 5, 2024
Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)

  • September 20, 2024
Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

  • May 20, 2024
Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis

  • May 20, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.